MX2022002339A - Derivados de alfa-d-galactopiranosido. - Google Patents
Derivados de alfa-d-galactopiranosido.Info
- Publication number
- MX2022002339A MX2022002339A MX2022002339A MX2022002339A MX2022002339A MX 2022002339 A MX2022002339 A MX 2022002339A MX 2022002339 A MX2022002339 A MX 2022002339A MX 2022002339 A MX2022002339 A MX 2022002339A MX 2022002339 A MX2022002339 A MX 2022002339A
- Authority
- MX
- Mexico
- Prior art keywords
- diyl
- formula
- galactopiranoside
- alpha
- derivatives
- Prior art date
Links
- -1 4,5-dihydroisoxazole-3,5-diyl Chemical group 0.000 abstract 7
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102000000802 Galectin 3 Human genes 0.000 abstract 1
- 108010001517 Galectin 3 Proteins 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/12—Triazine radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2019073063 | 2019-08-29 | ||
| PCT/EP2020/074121 WO2021038068A1 (en) | 2019-08-29 | 2020-08-28 | Alpha-d-galactopyranoside derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022002339A true MX2022002339A (es) | 2022-04-06 |
Family
ID=72561746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022002339A MX2022002339A (es) | 2019-08-29 | 2020-08-28 | Derivados de alfa-d-galactopiranosido. |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US12319672B2 (enExample) |
| EP (1) | EP4021904B1 (enExample) |
| JP (1) | JP7612669B2 (enExample) |
| KR (1) | KR102824799B1 (enExample) |
| CN (1) | CN114585619B (enExample) |
| AU (1) | AU2020338816B2 (enExample) |
| BR (1) | BR112022003562A2 (enExample) |
| CA (1) | CA3148365A1 (enExample) |
| ES (1) | ES2972551T3 (enExample) |
| HR (1) | HRP20240297T1 (enExample) |
| HU (1) | HUE066221T2 (enExample) |
| IL (1) | IL290815B2 (enExample) |
| MA (1) | MA57000B1 (enExample) |
| MX (1) | MX2022002339A (enExample) |
| MY (1) | MY207787A (enExample) |
| PH (1) | PH12022550436A1 (enExample) |
| PL (1) | PL4021904T3 (enExample) |
| RS (1) | RS65294B1 (enExample) |
| SA (1) | SA522431777B1 (enExample) |
| TW (1) | TWI864085B (enExample) |
| UA (1) | UA129205C2 (enExample) |
| WO (1) | WO2021038068A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102863667B1 (ko) | 2019-08-09 | 2025-09-23 | 이도르시아 파마슈티컬스 리미티드 | (2-아세트아미딜)티오-베타-d-갈락토피라노시드 유도체 |
| US12404295B2 (en) | 2019-08-09 | 2025-09-02 | Idorsia Pharmaceuticals Ltd | (Hetero)aryl-methyl-thio-beta-D-galactopyranoside derivatives |
| MA56883B1 (fr) | 2019-08-15 | 2025-04-30 | Idorsia Pharmaceuticals Ltd | Dérivés de 2-hydroxycycloalcane-1-carbamoyle |
| WO2022073969A1 (en) | 2020-10-06 | 2022-04-14 | Idorsia Pharmaceuticals Ltd | Spiro derivatives of alpha-d-galactopyranosides |
| US12291520B2 (en) | 2020-11-02 | 2025-05-06 | Idorsia Pharmaceuticals Ltd | Galectin-3 inhibiting 2-hydroxycycloalkane-1-carbamoyl derivatives |
| JP7844491B2 (ja) | 2021-02-09 | 2026-04-13 | イドルシア・ファーマシューティカルズ・リミテッド | ヒドロキシヘテロシクロアルカン－カルバモイル誘導体 |
| WO2022184755A1 (en) | 2021-03-03 | 2022-09-09 | Idorsia Pharmaceuticals Ltd | Triazolyl-methyl substituted alpha-d-galactopyranoside derivatives |
| WO2022250976A1 (en) * | 2021-05-28 | 2022-12-01 | Glycomimetics, Inc. | Galectin-3 inhibiting c-glycoside oximes |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0100172D0 (sv) | 2001-01-22 | 2001-01-22 | Ulf Nilsson | New inhibitors against galectins |
| SE0401301D0 (sv) * | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel 3-triazolyl-galactoside inhibitors of galectins |
| SE0401300D0 (sv) | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel Galactoside Inhibitors of Galectins |
| KR102231732B1 (ko) | 2012-10-10 | 2021-03-23 | 갈렉틴 테라퓨틱스, 인크. | 당뇨병성 신장병증 및 관련 질환의 치료를 위한 갈락토스 갈래의 탄수화물 화합물 |
| IN2015DN02573A (enExample) | 2012-10-31 | 2015-09-11 | Galecto Biotech Ab | |
| EP2919802A4 (en) | 2012-11-15 | 2016-09-14 | Univ Tufts | METHOD, COMPOSITIONS AND KITS FOR TREATING, MODULATING OR PREVENTING ANGIOGENESIS OR FIBROSIS IN A PATIENT USING A GALECTINE PROTEIN HEMMER |
| CA2970062C (en) * | 2015-01-30 | 2023-02-28 | Galecto Biotech Ab | Alpha-d-galactoside inhibitors of galectins |
| ES2734713T3 (es) | 2015-07-06 | 2019-12-11 | Gilead Sciences Inc | Moduladores Cot y métodos de utilización de los mismos |
| CN109563119A (zh) * | 2016-07-12 | 2019-04-02 | 格莱克特生物技术公司 | 半乳糖凝集素的α-D-半乳糖苷抑制剂 |
| CA3062649A1 (en) | 2017-05-12 | 2018-11-15 | Galectin Sciences, Llc | Compounds for the treatment of systemic insulin resistance disorders and the use thereof |
| KR102626669B1 (ko) | 2017-05-12 | 2024-01-17 | 갈랙틴 사이언시즈, 엘엘씨 | 질환의 예방 및 치료를 위한 화합물 및 이의 용도 |
| US11267811B2 (en) | 2017-09-27 | 2022-03-08 | Bristol-Myers Squibb Company | Small molecule inhibitors of galectin-3 |
| WO2019075045A1 (en) | 2017-10-11 | 2019-04-18 | Bristol-Myers Squibb Company | INHIBITORS WITH SMALL MOLECULES OF GALECTIN-3 |
| JP2021501180A (ja) * | 2017-10-31 | 2021-01-14 | ガレクティン・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＧａｌｅｃｔｉｎ Ｓｃｉｅｎｃｅｓ， ＬＬＣ | 全身インスリン抵抗性障害の治療のためのセレノガラクトシド化合物およびその使用 |
| CN113286632A (zh) | 2018-10-15 | 2021-08-20 | 格莱克特生物技术公司 | 半乳糖凝集素的半乳糖苷抑制剂前药 |
| CN113366007A (zh) | 2018-10-15 | 2021-09-07 | 格莱克特生物技术公司 | 半乳糖凝集素的半乳糖苷抑制剂 |
| US11447517B2 (en) | 2018-11-21 | 2022-09-20 | Galecto Biotech Ab | Galactoside inhibitor of galectins |
| US12269819B2 (en) | 2019-04-10 | 2025-04-08 | Bristol-Myers Squibb Company | Small molecule inhibitors of Galectin-3 |
| JP7674276B2 (ja) | 2019-07-03 | 2025-05-09 | ガレクト バイオテック エービー | ガレクチンの新規なガラクトシド阻害剤 |
| CA3143078A1 (en) | 2019-07-05 | 2021-01-14 | Galecto Biotech Ab | Novel galactoside inhibitor of galectins |
| US12404295B2 (en) | 2019-08-09 | 2025-09-02 | Idorsia Pharmaceuticals Ltd | (Hetero)aryl-methyl-thio-beta-D-galactopyranoside derivatives |
| KR102863667B1 (ko) | 2019-08-09 | 2025-09-23 | 이도르시아 파마슈티컬스 리미티드 | (2-아세트아미딜)티오-베타-d-갈락토피라노시드 유도체 |
| MA56883B1 (fr) | 2019-08-15 | 2025-04-30 | Idorsia Pharmaceuticals Ltd | Dérivés de 2-hydroxycycloalcane-1-carbamoyle |
| WO2022073969A1 (en) | 2020-10-06 | 2022-04-14 | Idorsia Pharmaceuticals Ltd | Spiro derivatives of alpha-d-galactopyranosides |
| US12291520B2 (en) | 2020-11-02 | 2025-05-06 | Idorsia Pharmaceuticals Ltd | Galectin-3 inhibiting 2-hydroxycycloalkane-1-carbamoyl derivatives |
| JP7844491B2 (ja) | 2021-02-09 | 2026-04-13 | イドルシア・ファーマシューティカルズ・リミテッド | ヒドロキシヘテロシクロアルカン－カルバモイル誘導体 |
| WO2022184755A1 (en) | 2021-03-03 | 2022-09-09 | Idorsia Pharmaceuticals Ltd | Triazolyl-methyl substituted alpha-d-galactopyranoside derivatives |
-
2020
- 2020-08-28 CN CN202080060134.6A patent/CN114585619B/zh active Active
- 2020-08-28 IL IL290815A patent/IL290815B2/en unknown
- 2020-08-28 RS RS20240319A patent/RS65294B1/sr unknown
- 2020-08-28 US US17/638,799 patent/US12319672B2/en active Active
- 2020-08-28 PH PH1/2022/550436A patent/PH12022550436A1/en unknown
- 2020-08-28 KR KR1020227009790A patent/KR102824799B1/ko active Active
- 2020-08-28 HR HRP20240297TT patent/HRP20240297T1/hr unknown
- 2020-08-28 MY MYPI2022001043A patent/MY207787A/en unknown
- 2020-08-28 MX MX2022002339A patent/MX2022002339A/es unknown
- 2020-08-28 ES ES20775188T patent/ES2972551T3/es active Active
- 2020-08-28 BR BR112022003562A patent/BR112022003562A2/pt unknown
- 2020-08-28 CA CA3148365A patent/CA3148365A1/en active Pending
- 2020-08-28 EP EP20775188.4A patent/EP4021904B1/en active Active
- 2020-08-28 PL PL20775188.4T patent/PL4021904T3/pl unknown
- 2020-08-28 WO PCT/EP2020/074121 patent/WO2021038068A1/en not_active Ceased
- 2020-08-28 AU AU2020338816A patent/AU2020338816B2/en active Active
- 2020-08-28 HU HUE20775188A patent/HUE066221T2/hu unknown
- 2020-08-28 UA UAA202201022A patent/UA129205C2/uk unknown
- 2020-08-28 MA MA57000A patent/MA57000B1/fr unknown
- 2020-08-28 TW TW109129635A patent/TWI864085B/zh active
- 2020-08-28 JP JP2022512854A patent/JP7612669B2/ja active Active
-
2022
- 2022-02-27 SA SA522431777A patent/SA522431777B1/ar unknown
-
2025
- 2025-04-29 US US19/193,332 patent/US20250257056A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| HUE066221T2 (hu) | 2024-07-28 |
| US20220281855A1 (en) | 2022-09-08 |
| BR112022003562A2 (pt) | 2022-05-24 |
| US12319672B2 (en) | 2025-06-03 |
| CN114585619B (zh) | 2024-09-27 |
| TW202122092A (zh) | 2021-06-16 |
| EP4021904B1 (en) | 2024-01-03 |
| WO2021038068A1 (en) | 2021-03-04 |
| MY207787A (en) | 2025-03-19 |
| TWI864085B (zh) | 2024-12-01 |
| HRP20240297T1 (hr) | 2024-05-10 |
| EP4021904A1 (en) | 2022-07-06 |
| KR102824799B1 (ko) | 2025-06-24 |
| SA522431777B1 (ar) | 2024-04-30 |
| PH12022550436A1 (en) | 2022-12-19 |
| IL290815A (en) | 2022-04-01 |
| IL290815B1 (en) | 2025-04-01 |
| AU2020338816A1 (en) | 2022-04-14 |
| EP4021904C0 (en) | 2024-01-03 |
| UA129205C2 (uk) | 2025-02-05 |
| ES2972551T3 (es) | 2024-06-13 |
| CA3148365A1 (en) | 2021-03-04 |
| RS65294B1 (sr) | 2024-04-30 |
| JP7612669B2 (ja) | 2025-01-14 |
| CN114585619A (zh) | 2022-06-03 |
| JP2022546029A (ja) | 2022-11-02 |
| PL4021904T3 (pl) | 2024-05-13 |
| AU2020338816B2 (en) | 2026-01-08 |
| US20250257056A1 (en) | 2025-08-14 |
| IL290815B2 (en) | 2025-08-01 |
| KR20220053622A (ko) | 2022-04-29 |
| MA57000B1 (fr) | 2024-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019003281A1 (es) | Derivados de piperidina. (divisional solicitud 201900169) | |
| CO2022015054A2 (es) | [1,3]diazino[5,4-d]pirimidinas como inhibidores de her2 | |
| BR112021021718A2 (pt) | Moduladores de thr-ss e métodos de uso dos mesmos | |
| CL2019001077A1 (es) | Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f] isoquinolina útiles en el tratamiento del cáncer. | |
| PH12022550436A1 (en) | Alpha-d-galactopyranoside derivatives | |
| CL2021001396A1 (es) | Derivados de panteteína y usos de los mismos | |
| UY30912A1 (es) | Derivados de 4-pirazol amidas conteniendo carboxi, sales farmacéuticamente aceptables de los mismo, composiciones farmacéuticas conteniéndolos, procesos de preparacion y uso. | |
| CL2022003646A1 (es) | Derivados de amidopirimidona | |
| BR112021019256A2 (pt) | Moduladores de receptor x4 de proteína g relacionado a mas e produtos e métodos relacionados | |
| CL2023002322A1 (es) | Derivados de hidroxiheterocicloalquil-carbamoilo | |
| CL2023002578A1 (es) | Derivados de alfa-d-galatopiranosido triazolil-metil sustituidos | |
| MX2019013639A (es) | Derivados de indol n-sustituidos. | |
| CO2018001700A2 (es) | Derivados de n-[1h-bencimidazol-2-il] metil-pirazin-2-il-carboxamida, composiciones y procedimientos de preparación de los mismos | |
| MX2019008331A (es) | Derivados de amino-imidazopiridina novedosos como inhibidores de cinasa de janus y uso farmacéutico de estos. | |
| MX389786B (es) | Derivados de 4-metil 7-{[5-heterociclilpirazina-2-il]amino}1,2- dihidro-1,6-naftiridina-5-ona como compuestos inhibidores de cdk4/6 y el uso de los mismos para el tratamiento de cáncer. | |
| BR112021018692A2 (pt) | 1,1-dióxido de isotiazolidina e 1,4-butanossultona contendo derivados de rapamicina e usos dos mesmos | |
| CL2020001817A1 (es) | Moduladores del receptor c5a | |
| DOP2022000073A (es) | Derivados de 2-azaspiro[3,4]octano como agonistas de m4 | |
| DOP2021000103A (es) | Pirazoles como moduladores de hemoglobina | |
| CL2021003348A1 (es) | Derivados de piridin–3–ilo. | |
| CL2023003951A1 (es) | Inhibidores de transglutaminasas | |
| ECSP22027784A (es) | Derivados de 2azaespiro[3.4]octano como agonistas de m4 | |
| CO4980875A1 (es) | Nuevos derivados de la equinocandina, su procedimiento de preparacion y su aplicacion como fungicidas | |
| CL2023000970A1 (es) | Espiro derivados de alfa-d-galactopiranosidos | |
| AR124720A1 (es) | Derivados de pirazolamida |